Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul;60(7):e71214.
doi: 10.1002/ppul.71214.

Disorders of Gut-Brain Interaction in a Pediatric Cystic Fibrosis Cohort

Jemilla Strode Smith  1 , Michael J Coffey  1   2 , Adam Jaffe  1   3 , Sandra Chuang  1   3 , Bernadette Prentice  1   3 , Josie van Dorst  1 , Chee Y Ooi  1   2
Affiliations
Observational Study

Disorders of Gut-Brain Interaction in a Pediatric Cystic Fibrosis Cohort

Jemilla Strode Smith et al. Pediatr Pulmonol. 2025 Jul.

Abstract

Introduction: Disorders of gut-brain interaction (DGBI), such as irritable bowel syndrome, occur at a higher prevalence in adults with cystic fibrosis (CF), compared to the general population. DGBI are associated with impaired quality of life and significant health-system costs. This study aimed to assess the proportion of cwCF with DGBI, compared to non-CF controls.

Methods: Validated for the assessment of DGBI, ROME IV surveys were distributed to cwCF and non-CF controls aged 0-18 years as part of the Evaluating the Alimentary Tracts in Health and Disease (EARTH) observational study. CF participants were recruited from the Sydney Children's Hospital (SCH) CF outpatient clinic between 2018 and 2022. Non-CF controls were recruited from outpatient clinics, advertisements, and word-of-mouth.

Results: Forty-four cwCF (female = 22 [50%], median [IQR] age = 7.04 [2.25-11.06] years) and 48 non-CF controls (female = 22 [45.83%], median (IQR) age = 8.04 [3.57-12.77] years) completed baseline surveys. Symptoms consistent with at least one DGBI were observed more frequently in cwCF compared to non-CF controls (36.36% vs. 10.42%%, p = 0.01). Functional abdominal pain was experienced at a higher prevalence in cwCF compared to non-CF controls (13.79% vs. 0%, p = 0.02). No significant differences in the prevalence of other specific disorders were observed between cwCF and non-CF controls.

Conclusion: Compared to non-CF, cwCF were significantly more likely to experience functional abdominal pain, and at least one DGBI collectively. Further large-scale studies are needed to validate our findings and ascertain the role of routine screening of DGBI in pediatric CF cohorts.

Keywords: DGBI; cystic fibrosis; disorders of gut‐brain interaction; functional gastrointestinal disorder.

PubMed Disclaimer

Conflict of interest statement

C.Y.O. has served as a consultant and received research funding from Vertex Pharmaceuticals (unrelated to this manuscript). B.P. has received Honorarium funding from Vertex Pharmaceuticals (unrelated to the manuscript). The other authors declare no conflicts of interest.

Similar articles

  • Dietary interventions for recurrent abdominal pain in childhood.
    Newlove-Delgado TV, Martin AE, Abbott RA, Bethel A, Thompson-Coon J, Whear R, Logan S. Newlove-Delgado TV, et al. Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD010972. doi: 10.1002/14651858.CD010972.pub2. Cochrane Database Syst Rev. 2017. PMID: 28334433 Free PMC article.
  • Long-Term Impact of COVID-19 on Disorders of Gut-Brain Interaction: Incidence, Symptom Burden, and Psychological Comorbidities.
    Marasco G, Hod K, Colecchia L, Cremon C, Barbaro MR, Cacciari G, Falangone F, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ, Koc ES, Sirin G, Calıskan AR, Bengi G, Alıs EE, Lukic S, Trajkovska M, Dumitrascu D, Pietrangelo A, Corradini E, Simren M, Sjolund J, Tornkvist N, Ghoshal UC, Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, Danese S, Portincasa P, Di Sabatino A, Maggio M, Philippou E, Lee YY, Salvi D, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; GI‐COVID19 study groups. Marasco G, et al. United European Gastroenterol J. 2025 Jun;13(5):798-818. doi: 10.1002/ueg2.70005. Epub 2025 Mar 21. United European Gastroenterol J. 2025. PMID: 40119532 Free PMC article.
  • Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.
    Jahnke N, Waters V, Ratjen F, Smith S, Hambleton IR, Scharf N. Jahnke N, et al. Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039. Cochrane Database Syst Rev. 2025. PMID: 40145528
  • Macrolide antibiotics (including azithromycin) for cystic fibrosis.
    Southern KW, Solis-Moya A, Kurz D, Smith S. Southern KW, et al. Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5. Cochrane Database Syst Rev. 2024. PMID: 38411248 Free PMC article.
  • Disorders of the gut-brain interaction among European people with obesity: Prevalence and burden of compatible symptoms.
    Melchior C, Hreinsson JP, Tack J, Keller J, Aziz Q, Palsson OS, Bangdiwala SI, Sperber AD, Simrén M, Sabaté JM. Melchior C, et al. United European Gastroenterol J. 2025 Jul;13(6):917-928. doi: 10.1002/ueg2.12700. Epub 2025 Apr 7. United European Gastroenterol J. 2025. PMID: 40195288 Free PMC article.
See all similar articles

References

    1. Rowbotham N. J., Smith S., Elliott Z. C., et al., “A Refresh of the Top 10 Research Priorities in Cystic Fibrosis,” Thorax 78 (2023): 840–843. - PMC - PubMed
    1. Schwarzenberg S. J., Vu P. T., Skalland M., et al., “Elexacaftor/Tezacaftor/Ivacaftor and Gastrointestinal Outcomes in Cystic Fibrosis: Report of Promise‐GI,” Journal of Cystic Fibrosis 22 (2023): 282–289. - PMC - PubMed
    1. Tabori H., Barucha A., Zagoya C., et al., “Scoring Abdominal Symptoms in People With Cystic Fibrosis,” Journal of Clinical Medicine 13 (2024): 1650. - PMC - PubMed
    1. Freeman A. J., Sathe M., Aliaj E., et al., “Designing the GALAXY Study: Partnering With the Cystic Fibrosis Community to Optimize Assessment of Gastrointestinal Symptoms,” Journal of Cystic Fibrosis 20 (2021): 598–604. - PMC - PubMed
    1. Drossman D. A. and Hasler W. L., “Rome IV‐Functional GI Disorders: Disorders of Gut‐Brain Interaction,” Gastroenterology 150 (2016): 1257–1261. - PubMed

Publication types

MeSH terms